10-Q: Agios Q3 2025: PYRUKYND Sales Rise, Thalassemia Approval Delayed

Agios Pharmaceuticals reports increased PYRUKYND product revenue in Q3 2025, but faces a three-month FDA review extension for PYRUKYND in thalassemia due to a REMS submission.

Summary

• Net loss for the three months ended September 30, 2025, was $(103.4) million, compared to net income of $947.9 million for the same period in 2024, which included significant one-time gains.
• Net loss for the nine months ended September 30, 2025, was $(304.7) million, compared to net income of $770.2 million for the same period in 2024, also influenced by one-time gains.
• Product revenue, net, increased to $12.88 million for Q3 2025 from $8.964 million in Q3 2024, driven by increased volume of PYRUKYND sales.
• Product revenue, net, for the nine months ended September 30, 2025, was $34.061 million, up from $25.768 million for the same period in 2024.
• Research and development expenses rose to $86.796 million in Q3 2025 from $72.455 million in Q3 2024, primarily due to increased costs for tebapivat clinical trials and PYRUKYND pediatric thalassemia trials.
• Selling, general and administrative expenses increased to $41.274 million in Q3 2025 from $38.537 million in Q3 2024, driven by commercialization activities for potential PYRUKYND thalassemia approval.
• Cash, cash equivalents, and marketable securities totaled $1.3 billion as of September 30, 2025.
• The FDA PDUFA goal date for PYRUKYND in thalassemia was extended by three months to December 7, 2025, following the submission of a proposed Risk Evaluation and Mitigation Strategy (REMS).
• The Saudi Food and Drug Authority approved PYRUKYND for adult patients with non-transfusion dependent and transfusion-dependent alphaor beta-thalassemia in August 2025.
• The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion for PYRUKYND in thalassemia in October 2025, with a final European Commission decision expected by early 2026.
• Enrollment for the Phase 3 portion of the RISE UP trial (PYRUKYND in Sickle Cell Disease) has been completed, with topline data expected in late 2025.
• Enrollment for the Phase 2b portion of the tebapivat trial in lower-risk myelodysplastic syndromes (LR MDS) was completed in September 2025, with topline data expected in early 2026.
• A Phase 1 clinical trial for AG-236 (targeting polycythemia vera) was initiated in July 2025, following IND clearance in June 2025.

Sentiment

Score: 4

Explanation: While product revenue is growing and there are positive regulatory opinions in other regions, the significant net loss (compared to prior year's one-time gains) and the FDA approval delay for a key indication for PYRUKYND, coupled with increasing operating expenses, temper the overall sentiment. The long-term pipeline progress is good, but the immediate financial picture and regulatory setback are concerning.

Positives

• Product revenue, net, increased by $3.9 million to $12.88 million for Q3 2025 compared to Q3 2024, and by $8.3 million to $34.061 million for the nine months ended September 30, 2025, compared to the same period in 2024, indicating growing sales volume for PYRUKYND.
• Maintained a strong liquidity position with $1.3 billion in cash, cash equivalents, and marketable securities as of September 30, 2025, expected to fund operations for at least the next twelve months.
• PYRUKYND received approval from the Saudi Food and Drug Authority in August 2025 for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alphaor beta-thalassemia.
• The CHMP of the EMA adopted a positive opinion for PYRUKYND for the new thalassemia indication in October 2025, signaling likely European Commission approval by early 2026.
• Completed enrollment for the Phase 3 portion of the RISE UP trial for PYRUKYND in Sickle Cell Disease, with topline data anticipated in late 2025, potentially leading to a U.S. commercial launch in 2026.
• Completed enrollment for the Phase 2b clinical trial of tebapivat in LR MDS, with topline data expected in early 2026.
• Initiated a Phase 1 clinical trial for AG-236 (for polycythemia vera) in July 2025, following IND clearance in June 2025, expanding the pipeline.

Negatives

• Reported a net loss of $(103.4) million for Q3 2025, a significant decline from the net income of $947.9 million in Q3 2024, primarily due to the absence of one-time gains from the sale of contingent payments and milestone payments received in the prior year.
• The FDA PDUFA goal date for PYRUKYND in thalassemia was extended by three months to December 7, 2025, due to the submission of a proposed Risk Evaluation and Mitigation Strategy (REMS), delaying potential U.S. approval and commercialization.
• Research and development expenses increased by $14.3 million in Q3 2025 and $33.0 million for the nine months ended September 30, 2025, reflecting higher costs for clinical trials and pipeline expansion.
• Selling, general and administrative expenses increased by $2.7 million in Q3 2025 and $23.6 million for the nine months ended September 30, 2025, indicating rising commercialization costs.
• The company expects to continue incurring significant operating losses for the foreseeable future, and has an accumulated deficit of $(453.7) million as of September 30, 2025.
• Hepatocellular injury was identified as an important potential risk of PYRUKYND in thalassemia patients, leading to the requirement for a REMS and monthly liver test monitoring.

Risks

• Failure to successfully commercialize PYRUKYND and other products for which approval is received.
• Inability to obtain marketing approval for PYRUKYND in thalassemia in all jurisdictions or for sickle cell disease (SCD).
• Clinical trials of product candidates may not be successful, leading to delays or abandonment of development programs.
• Product candidates may have undesirable side effects or unexpected characteristics, such as the hepatocellular injury observed with PYRUKYND, which could lead to delays, denials, or restrictive labels.
• Difficulties in patient enrollment for clinical trials, particularly for orphan diseases, could delay or prevent trial completion.
• Results of preclinical studies and early clinical trials may not be predictive of success in later-stage clinical trials.
• Interim and preliminary data from clinical trials may change as more patient data becomes available and is subject to audit and verification.
• The FDA may not accept data from clinical trials conducted outside the United States, requiring additional costly and time-consuming trials.
• Limited financial and managerial resources may be expended on product candidates or indications that prove less profitable or have a lower likelihood of success.
• PYRUKYND or any future approved product candidates may fail to achieve sufficient market acceptance by physicians, patients, and healthcare payors.
• Inability to maintain sales and marketing capabilities or enter into effective distribution agreements with third parties.
• Failure to achieve projected development or regulatory approval estimates in announced timeframes could delay commercialization and negatively impact stock price.
• Substantial competition from major pharmaceutical and biotechnology companies, academic institutions, and other research organizations.
• Generic or follow-on competition could adversely affect sales if appropriate periods of regulatory exclusivity are not granted or maintained.
• Product liability lawsuits could result in substantial liabilities, decreased demand, and reputational harm.
• Internal information technology systems or those of third parties may fail or suffer security breaches, leading to data loss, operational disruptions, and potential legal liabilities.
• Non-compliance with stringent privacy laws and regulations (e.g., HIPAA, GDPR) could result in significant fines, penalties, and reputational damage.
• Challenges as a less diversified company following the sale of the oncology business, increasing susceptibility to market conditions in rare diseases.
• Raising additional capital through equity or convertible debt securities may dilute stockholder ownership or impose restrictive covenants.
• Expectation to incur significant operating losses in the future and potential inability to achieve or maintain profitability.
• Changes in tax laws or their implementation/interpretation (e.g., Inflation Reduction Act, One Big Beautiful Bill Act) may adversely affect financial condition.
• Reliance on third-party contract research organizations (CROs) and manufacturers, who may not perform satisfactorily or meet deadlines.
• Adverse impacts from geopolitical events, rising global energy costs, or supply chain disruptions could delay product development and commercialization.
• The CREATES Act exposes the company to potential litigation and damages by competitors claiming insufficient product quantities for generic testing.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Inability to retain key executives and scientific leadership or attract, retain, and motivate qualified personnel.
• Employee misconduct or noncompliance with regulatory standards and requirements could lead to criminal sanctions, civil penalties, and reputational harm.
• Provisions in corporate charter documents and Delaware law could make an acquisition of the company more difficult.
• The price of common stock is volatile and subject to wide fluctuations.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited due to ownership changes or regulatory changes.

Future Outlook

The company expects to continue incurring significant expenses and net losses for the foreseeable future until it achieves profitability. Existing cash, cash equivalents, and marketable securities of $1.3 billion as of September 30, 2025, are anticipated to be sufficient to fund current operations for at least the next twelve months. Selling, general and administrative expenses are expected to increase to support ongoing research and development and commercialization activities, particularly for the potential approval of PYRUKYND in thalassemia. Research and development costs are also projected to rise as product candidate development programs advance. The company anticipates a potential U.S. commercial launch of PYRUKYND in Sickle Cell Disease in 2026, if approved, and expects a final European Commission decision for PYRUKYND in thalassemia by early 2026. Topline data for the tebapivat Phase 2b trial in LR MDS is expected in early 2026, and for the PYRUKYND Phase 3 trial in SCD in late 2025. The company may also pursue opportunistic debt or equity offerings to secure additional funding.

Management Comments

• We champion an inclusive culture that fosters bold innovation and collaboration, both within our teams and with the rare disease communities we serve.
• By building deep connections and trusted partnerships with patients, advocates, and healthcare professionals, we advance our understanding of the unique priorities and needs of these communities. These real-world insights, combined with our biological expertise, allow us to develop and deliver innovative medicines with the potential to transform lives.
• Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Industry Context

The company operates in the highly competitive biopharmaceutical sector, specifically targeting rare diseases. Its lead product, PYRUKYND, and pipeline candidates like tebapivat, AG-181, and AG-236, face significant competition from established pharmaceutical giants and emerging biotechnology firms. Competitors are actively developing or marketing therapies for conditions such as PK deficiency, thalassemia, sickle cell disease, myelodysplastic syndromes, phenylketonuria, and polycythemia vera. The industry is also navigating increasing regulatory scrutiny on drug pricing, potential impacts from legislative changes like the Inflation Reduction Act and the One Big Beautiful Bill Act, and evolving trade policies, including potential tariffs on imported drugs. Patient enrollment for clinical trials in orphan diseases remains a persistent challenge across the industry.

Comparison to Industry Standards

• For beta thalassemia and lower-risk myelodysplastic syndromes (LR MDS), Merck and Bristol-Myers Squibb Company (BMS) are marketing therapies and conducting clinical trials, while Geron Corporation recently received FDA approval for an LR MDS treatment.
• In sickle cell disease (SCD), Novartis International AG and Emmaus Life Sciences are marketing therapies, with Pfizer Inc., CSL Behring, Cellarity, Inc., Novo Nordisk A/S, Sanofi, Genetix Biotherapeutics Inc., Vertex, CRISPR, Disc Medicine, Inc., Fulcrum Therapeutics Inc., and BMS all conducting clinical trials for potential treatments.
• For phenylketonuria (PKU), BioMarin Pharmaceutical Inc. and PTC Therapeutics, Inc. market therapies, while Otsuka Pharmaceutical Co., Ltd, NGGT Inc., and Maze Therapeutics, Inc. are conducting clinical trials.
• In polycythemia vera (PV), PharmaEssentia Corp and Incyte Corporation market therapies, and Protagonist Therapeutics with Takeda, Ionis Pharmaceuticals, Inc. with Ono Pharmaceutical Co., Ltd, Italfarmaco S.p.A., Disc Medicine, Inc., Merck & Co., Inc., GluBio Inc., and Silence Therapeutics are developing therapies.
• Rocket Pharma LTD is developing a therapy for PK deficiency, directly competing with PYRUKYND.
• The company acknowledges the industry-wide challenge that many compounds showing early promise in preclinical and early-stage clinical trials often fail in later stages due to side effects or lack of efficacy, a common hurdle in drug development.

Management Changes

Corporate Governance

Legal Proceedings

• The company is exposed to potential product liability lawsuits related to its product candidates in clinical trials and commercially sold medicines, including PYRUKYND.
• There is a risk of patent interference, derivation, inter partes review, post-grant review, reexamination, or patent infringement claims challenging the company's patent rights or those of others.
• The company may become involved in lawsuits to protect or enforce its patents and other intellectual property rights, which can be expensive, time-consuming, and have uncertain outcomes.
• Third parties may initiate legal proceedings alleging infringement of their intellectual property rights, which could require obtaining licenses, ceasing development/commercialization, or incurring monetary damages.
• The company may be subject to claims that employees have wrongfully used or disclosed alleged trade secrets of former employers.
• The CREATES Act exposes the company to possible litigation and damages by competitors who may claim insufficient quantities of approved products are provided for testing in support of ANDAs and 505(b)(2) applications.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and stock price volatility, with capital appreciation being the sole source of gain as no cash dividends are anticipated.
• Patients may benefit from new treatments for rare diseases, but also face risks of side effects (e.g., hepatocellular injury with PYRUKYND) and potential delays in drug availability due to regulatory processes.
• Employees are impacted by stock-based compensation and the company's ability to retain key personnel, with a flexible workplace policy potentially affecting corporate culture.
• Customers (specialty distributors and pharmacies) continue to generate revenue from PYRUKYND sales, but are subject to pricing and reimbursement policies.
• Suppliers, CROs, and manufacturers are critical partners, and their performance or supply chain disruptions could impact the company's development and commercialization efforts.
• Regulatory bodies (FDA, EMA, SFDA) are actively reviewing submissions and enforcing compliance, which can lead to delays or additional requirements for product approvals.
• Creditors and investors are impacted by the company's financial performance, including recurring losses and the need for future capital, as well as the success of its pipeline.

Next Steps

• FDA review of PYRUKYND sNDA for thalassemia, with a PDUFA goal date of December 7, 2025.
• European Commission review of CHMP's positive opinion for PYRUKYND in thalassemia, with a final decision expected by early 2026.
• Announce topline data for PYRUKYND Phase 3 trial in Sickle Cell Disease (RISE UP) in late 2025.
• Potential U.S. commercial launch of PYRUKYND in Sickle Cell Disease in 2026, if approved.
• Announce topline data for Tebapivat Phase 2b trial in lower-risk myelodysplastic syndromes (LR MDS) in early 2026.
• Continue evaluating PYRUKYND for Sickle Cell Disease and in pediatric patients with PK deficiency.
• Continue clinical development of tebapivat for LR MDS and Sickle Cell Disease.
• Continue clinical development of AG-181 for phenylketonuria (PKU).
• Continue clinical development of AG-236 for polycythemia vera (PV).
• Expand and protect the intellectual property portfolio, including in-licensing or acquiring assets for pipeline growth.
• Hire additional commercial and development personnel to support growth.
• Evaluate other options for commercialization of PYRUKYND outside the United States, including exploring potential partnership opportunities.

Key Dates

Recommendation

The company shows promising pipeline progress with multiple candidates advancing and positive regulatory opinions in key markets for PYRUKYND in thalassemia. However, the three-month FDA delay for PYRUKYND in thalassemia, coupled with a significant net loss (albeit compared to a prior year with large one-time gains) and rising operating expenses, introduces near-term uncertainty. The strong cash position provides a buffer for continued development, but investors should monitor the resolution of the FDA delay and the commercial launch trajectory for PYRUKYND in new indications before making a more aggressive move.

Keywords

Biopharmaceutical, Rare Disease, PYRUKYND, Mitapivat, PK Deficiency, Thalassemia, Sickle Cell Disease, Myelodysplastic Syndromes, Phenylketonuria, Polycythemia Vera, Clinical Trials, FDA Approval, EMA, Drug Development, SEC Filing, 10-Q, Financial Results, Biotechnology, Pharmaceutical